vs
GLADSTONE COMMERCIAL CORP(GOOD)与RECURSION PHARMACEUTICALS, INC.(RXRX)财务数据对比。点击上方公司名可切换其他公司
GLADSTONE COMMERCIAL CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.2倍($43.5M vs $35.5M),GLADSTONE COMMERCIAL CORP净利率更高(12.4% vs -304.2%,领先316.6%),RECURSION PHARMACEUTICALS, INC.同比增速更快(681.7% vs 16.3%),过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高(60.5% vs 10.3%)
格拉德斯通商业公司是一家上市房地产投资信托,主要在美国境内收购、持有及运营多元化的工业与商业地产组合,面向制造、物流、医疗、专业服务等领域的租户提供长期净租赁服务,核心客群为中小规模企业。
Recursion Pharmaceuticals是一家临床阶段生物技术企业,依托人工智能技术和高通量生物实验体系,开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法,核心市场覆盖北美,与全球多家生物制药企业合作推进在研管线落地。
GOOD vs RXRX — 直观对比
营收规模更大
GOOD
是对方的1.2倍
$35.5M
营收增速更快
RXRX
高出665.5%
16.3%
净利率更高
GOOD
高出316.6%
-304.2%
两年增速更快
RXRX
近两年复合增速
10.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $43.5M | $35.5M |
| 净利润 | $5.4M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 12.4% | -304.2% |
| 营收同比 | 16.3% | 681.7% |
| 净利润同比 | -25.1% | 39.6% |
| 每股收益(稀释后) | $0.05 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
GOOD
RXRX
| Q4 25 | $43.5M | $35.5M | ||
| Q3 25 | $40.8M | $5.2M | ||
| Q2 25 | $39.5M | $19.2M | ||
| Q1 25 | $37.5M | $14.7M | ||
| Q4 24 | $37.4M | $4.5M | ||
| Q3 24 | $39.2M | $26.1M | ||
| Q2 24 | $37.1M | $14.4M | ||
| Q1 24 | $35.7M | $13.8M |
净利润
GOOD
RXRX
| Q4 25 | $5.4M | $-108.1M | ||
| Q3 25 | $4.1M | $-162.3M | ||
| Q2 25 | $4.6M | $-171.9M | ||
| Q1 25 | $5.1M | $-202.5M | ||
| Q4 24 | $7.2M | $-178.9M | ||
| Q3 24 | $11.7M | $-95.8M | ||
| Q2 24 | $1.6M | $-97.5M | ||
| Q1 24 | $3.5M | $-91.4M |
毛利率
GOOD
RXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率
GOOD
RXRX
| Q4 25 | — | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | — | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率
GOOD
RXRX
| Q4 25 | 12.4% | -304.2% | ||
| Q3 25 | 10.1% | -3135.3% | ||
| Q2 25 | 11.7% | -894.2% | ||
| Q1 25 | 13.7% | -1373.3% | ||
| Q4 24 | 19.2% | -3935.5% | ||
| Q3 24 | 29.8% | -367.5% | ||
| Q2 24 | 4.3% | -676.6% | ||
| Q1 24 | 9.9% | -662.4% |
每股收益(稀释后)
GOOD
RXRX
| Q4 25 | $0.05 | $-0.17 | ||
| Q3 25 | $0.02 | $-0.36 | ||
| Q2 25 | $0.03 | $-0.41 | ||
| Q1 25 | $0.04 | $-0.50 | ||
| Q4 24 | $0.10 | $-0.56 | ||
| Q3 24 | $0.20 | $-0.34 | ||
| Q2 24 | $-0.04 | $-0.40 | ||
| Q1 24 | $0.01 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $10.8M | $743.3M |
| 总债务越低越好 | $843.5M | $9.6M |
| 股东权益账面价值 | $171.8M | $1.1B |
| 总资产 | $1.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 4.91× | 0.01× |
8季度趋势,按日历期对齐
现金及短期投资
GOOD
RXRX
| Q4 25 | $10.8M | $743.3M | ||
| Q3 25 | $18.4M | $659.8M | ||
| Q2 25 | $11.7M | $525.1M | ||
| Q1 25 | $10.4M | $500.5M | ||
| Q4 24 | $11.0M | $594.4M | ||
| Q3 24 | $10.5M | $427.6M | ||
| Q2 24 | $10.4M | $474.3M | ||
| Q1 24 | $10.5M | $296.3M |
总债务
GOOD
RXRX
| Q4 25 | $843.5M | $9.6M | ||
| Q3 25 | $843.3M | $11.9M | ||
| Q2 25 | $794.4M | $14.2M | ||
| Q1 25 | $740.7M | $16.4M | ||
| Q4 24 | $693.4M | $19.0M | ||
| Q3 24 | $692.6M | $20.5M | ||
| Q2 24 | $722.5M | $22.9M | ||
| Q1 24 | $719.4M | — |
股东权益
GOOD
RXRX
| Q4 25 | $171.8M | $1.1B | ||
| Q3 25 | $184.8M | $1.0B | ||
| Q2 25 | $177.2M | $919.1M | ||
| Q1 25 | $183.2M | $933.9M | ||
| Q4 24 | $171.2M | $1.0B | ||
| Q3 24 | $168.9M | $524.6M | ||
| Q2 24 | $145.7M | $584.4M | ||
| Q1 24 | $147.3M | $401.2M |
总资产
GOOD
RXRX
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.1B | $1.4B | ||
| Q3 24 | $1.1B | $726.5M | ||
| Q2 24 | $1.1B | $775.9M | ||
| Q1 24 | $1.1B | $557.8M |
负债/权益比
GOOD
RXRX
| Q4 25 | 4.91× | 0.01× | ||
| Q3 25 | 4.56× | 0.01× | ||
| Q2 25 | 4.48× | 0.02× | ||
| Q1 25 | 4.04× | 0.02× | ||
| Q4 24 | 4.05× | 0.02× | ||
| Q3 24 | 4.10× | 0.04× | ||
| Q2 24 | 4.96× | 0.04× | ||
| Q1 24 | 4.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $88.2M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 16.38× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势,按日历期对齐
经营现金流
GOOD
RXRX
| Q4 25 | $88.2M | $-46.1M | ||
| Q3 25 | $18.9M | $-117.4M | ||
| Q2 25 | $35.8M | $-76.4M | ||
| Q1 25 | $17.7M | $-132.0M | ||
| Q4 24 | $57.0M | $-115.4M | ||
| Q3 24 | $5.5M | $-59.2M | ||
| Q2 24 | $13.6M | $-82.2M | ||
| Q1 24 | $15.0M | $-102.3M |
自由现金流
GOOD
RXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率
GOOD
RXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度
GOOD
RXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率
GOOD
RXRX
| Q4 25 | 16.38× | — | ||
| Q3 25 | 4.57× | — | ||
| Q2 25 | 7.74× | — | ||
| Q1 25 | 3.44× | — | ||
| Q4 24 | 7.93× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 8.44× | — | ||
| Q1 24 | 4.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图